Ricolinostat (ACY-1215)
别名: Rocilinostat
Ricolinostat (ACY-1215, Rocilinostat) 是一种选择性HDAC6抑制剂，无细胞试验中IC50为5 nM，作用于HDAC6比作用于HDAC1/2/3(I型HDACs)选择性高10倍以上，对HDAC8具有微弱的作用活性，对HDAC4/5/7/9/11， Sirtuin1和Sirtuin2具有最小的作用活性。Ricolinostat (ACY-1215) 可抑制细胞增殖并促进凋亡。Phase 2。
Ricolinostat (ACY-1215) Chemical Structure
CAS: 1316214-52-4
客户使用Selleck的Ricolinostat (ACY-1215) 发表文献66篇
产品质控
批次：
纯度：
99.96%
99.96
常与Ricolinostat (ACY-1215) 一起在实验中被使用的化合物
与单独使用任一药物相比，Ricolinostat和Bendamustine在淋巴瘤细胞系中诱导显着更大的细胞凋亡。
Ricolinostat和Carfilzomib显着抑制MCL异种移植模型中的肿瘤生长。
Dasmahapatra G, et al. Mol Cancer Ther (2014) 13 (12): 2886–2897.
Ricolinostat和Crizotinib治疗显着抑制DLBCL细胞的细胞生长，并诱导NuDUL-1和Toledo细胞凋亡。
Ricolinostat增强Oxaliplatin在结直肠癌细胞中的抗癌活性。
Ricolinostat和JQ1增加细胞凋亡，减少c-MYC和BCL-2的表达，并降低多发性骨髓瘤细胞增殖。
Ricolinostat (ACY-1215) 相关产品
相关信号通路图
HDAC抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| SUP-B15 | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| SEM | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in human SEM cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| HL60 | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in human HL60 cells assessed as increase in cleaved PARP expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| SUP-B15 | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| SEM | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in human SEM cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| HL60 | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in human HL60 cells assessed as increase in acetyl-histone H3 expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| SUP-B15 | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in imatinib-resistant human SUP-B15 cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| SEM | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in human SEM cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| HL60 | Function assay | 0.1 to 10 uM | 24 hrs | Inhibition of HDAC6 in human HL60 cells assessed as increase in acetyl-alpha tubulin expression at 0.1 to 10 uM after 24 hrs by immunoblot assay | 30365892 |
| MV4-11 | Function assay | 1000 nM | 6 hrs | Inhibition of HDAC1/2/3 in human MV4-11 cells assessed as upregulation of histone H3 acetylation at 1000 nM after 6 hrs by Western blot analysis | 26443078 |
| OPM2 | Cell Viability Assay | 0-8μM | 48 h | decreases MM-cell viability in a dose-dependent manner | 22262760 |
| MM.1R | Cell Viability Assay | 0-8μM | 48 h | decreases MM-cell viability in a dose-dependent manner | 22262760 |
| LR5 | Cell Viability Assay | 0-8μM | 48 h | decreases MM-cell viability in a dose-dependent manner | 22262760 |
| RPMI | Cell Viability Assay | 0-8μM | 48 h | decreases MM-cell viability in a dose-dependent manner | 22262760 |
| OPM1 | Cell Viability Assay | 0-8μM | 48 h | decreases MM-cell viability in a dose-dependent manner | 22262760 |
| MM.1S | Cell Viability Assay | 0-8μM | 48 h | decreases MM-cell viability in a dose-dependent manner | 22262760 |
| RPMI8226 | Function Assay | 0.25/1μM | 18 h | increases acetylated α-tubulin | 22262760 |
| MM.1S | Function Assay | 0.25/1μM | 18 h | increases acetylated α-tubulin | 22262760 |
| MM.1R | Function Assay | 0.25/1μM | 18 h | increases acetylated α-tubulin | 22262760 |
| MM.1S | Function Assay | 0-5μM | 6 h | increases acetylated α-tubulin | 22262760 |
| A-172 | Growth Inhibition Assay | 10 nM | 24/48 h | inhibits cell growth time dependently | 26150340 |
| U87MG | Growth Inhibition Assay | 10 nM | 24/48 h | inhibits cell growth time dependently | 26150340 |
| HEL | Cell cycle assay | 1 to 10 uM | 48 hrs | Cell cycle arrest in human HEL cells assessed as accumulation at G1 phase at 1 to 10 uM after 48 hrs propidium iodide staining based flow cytometry | 29940115 |
| SEM | Function assay | 1.6 uM | 18 hrs | Inhibition of HDAC6 in human SEM cells assessed as decrease in aggresome accumulation at 1.6 uM after 18 hrs by FACS analysis | 30365892 |
| SH-SY5Y | Function assay | 0.1 to 1 uM | 24 hrs | Inhibition of HDAC6 in human SH-SY5Y cells assessed as increase in acetylation of alpha-tubulin at 0.1 to 1 uM after 24 hrs by Western blot analysis | 30028616 |
| SH-SY5Y | Function assay | 0.1 to 1 uM | 24 hrs | Inhibition of class 1 HDAC in human SH-SY5Y cells assessed as increase in acetylation of histone H3 at 0.1 to 1 uM after 24 hrs by Western blot analysis | 30028616 |
| BCP-ALL | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BCP-ALL cells derived from patient 3 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 4.45 μM. | 30365892 | |
| HEL | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay, IC50 = 3.75 μM. | 29940115 | |
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay, IC50 = 3.75 μM. | 29940115 | |
| HL60 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay, IC50 = 3.75 μM. | 29940115 | |
| KCL22 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.75 μM. | 30365892 | |
| SUP-B15 | Cytotoxicity assay | 72 hrs | Cytotoxicity against imatinib-resistant human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.54 μM. | 30365892 | |
| U266 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human U266 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.52 μM. | 30365892 | |
| KCL22 | Cytotoxicity assay | 72 hrs | Cytotoxicity against imatinib-resistant human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 3.38 μM. | 30365892 | |
| HEL | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 2.54 μM. | 29940115 | |
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 2.54 μM. | 29940115 | |
| HL60 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 2.54 μM. | 29940115 | |
| HL60 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HL60 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 2.36 μM. | 30365892 | |
| RPMI18226 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human RPMI18226 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 1.97 μM. | 30365892 | |
| SUP-B15 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 1.92 μM. | 30365892 | |
| SEM | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SEM cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 1.61 μM. | 30365892 | |
| RPMI8226 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay, IC50 = 1.468 μM. | 26443078 | |
| BCP-ALL | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BCP-ALL cells derived from patient 2 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 0.58 μM. | 30365892 | |
| BCP-ALL | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BCP-ALL cells derived from patient 4 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 0.54 μM. | 30365892 | |
| BCP-ALL | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BCP-ALL cells derived from patient 1 after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 0.29 μM. | 30365892 | |
| Sf9 | Function assay | 15 mins | Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence ass, IC50 = 0.1 μM. | 29500130 | |
| Sf9 | Function assay | 15 mins | Inhibition of full length recombinant human C-terminal His-tagged HDAC2 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay, IC50 = 0.066 μM. | 29500130 | |
| Sf9 | Function assay | 10 mins | Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins, IC50 = 0.058 μM. | 28038324 | |
| Sf9 | Function assay | 10 mins | Inhibition of full length human recombinant C-terminal FLAG-tagged HDAC2 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins, IC50 = 0.048 μM. | 28038324 | |
| Sf9 | Function assay | 15 mins | Inhibition of full length recombinant human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate additi, IC50 = 0.037 μM. | 29500130 | |
| Sf9 | Function assay | 15 mins | Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells using Boc-Lys-(Ac)-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay, IC50 = 0.009 μM. | 29500130 | |
| Sf9 | Function assay | 10 mins | Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in Sf9 cells using FTS as substrate preincubated for 10 mins followed by substrate addition measured over 30 mins, IC50 = 0.0047 μM. | 28038324 | |
| HH | Growth Inhibition Assay | 48 h | IC50=2.5 μM | 26116270 | |
| Sup-T1 | Growth Inhibition Assay | 48 h | IC50=1.6 μM | 26116270 | |
| CCL-119 | Growth Inhibition Assay | 48 h | IC50=1.7 μM | 26116270 | |
| H9 | Growth Inhibition Assay | 48 h | IC50=1.2 μM | 26116270 | |
| Rec-1 | Growth Inhibition Assay | 48 h | IC50=2.3 μM | 26116270 | |
| Jeko-1 | Growth Inhibition Assay | 48 h | IC50=1.5 μM | 26116270 | |
| Jvm-2 | Growth Inhibition Assay | 48 h | IC50=4.0 μM | 26116270 | |
| Su-DHL6 | Growth Inhibition Assay | 48 h | IC50=3.2 μM | 26116270 | |
| Hbl-2 | Growth Inhibition Assay | 48 h | IC50=1.9 μM | 26116270 | |
| Su-DHL4 | Growth Inhibition Assay | 48 h | IC50=4.7 μM | 26116270 | |
| OCI-Ly1 | Growth Inhibition Assay | 48 h | IC50=2.4 μM | 26116270 | |
| OCI-Ly7 | Growth Inhibition Assay | 48 h | IC50=1.2 μM | 26116270 | |
| Su-DHL2 | Growth Inhibition Assay | 48 h | IC50=3.3 μM | 26116270 | |
| OCI-Ly10 | Growth Inhibition Assay | 48 h | IC50=0.9 μM | 26116270 | |
| Riva | Growth Inhibition Assay | 48 h | IC50=2.2 μM | 26116270 | |
| Hbl-1 | Growth Inhibition Assay | 48 h | IC50=1.6 μM | 26116270 | |
| SEM | Antiproliferative assay | 24 to 72 hrs | Antiproliferative activity against human SEM cells at IC50 to 2 times IC50 after 24 to 72 hrs by trypan exclusion method | 30365892 | |
| SEM | Function assay | 18 hrs | Inhibition of HDAC6 in human SEM cells assessed as decrease in aggresome accumulation at IC50 after 18 hrs by fluorescence microscopic method | 30365892 | |
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Ricolinostat (ACY-1215, Rocilinostat) 是一种选择性HDAC6抑制剂，无细胞试验中IC50为5 nM，作用于HDAC6比作用于HDAC1/2/3(I型HDACs)选择性高10倍以上，对HDAC8具有微弱的作用活性，对HDAC4/5/7/9/11， Sirtuin1和Sirtuin2具有最小的作用活性。Ricolinostat (ACY-1215) 可抑制细胞增殖并促进凋亡。Phase 2。 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 特性 | ACY-1215作用于4名健康捐献者的PHA刺激的PBMCs，与pan-HDAC抑制剂SAHA相比，具有更低的细胞毒性。 | ||||||||||
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | ACY-1215是一种异羟肟酸类衍生物。ACY-1215作用于HDAC1, HDAC2, 和 HDAC3 (I型 HDACs)效果分别低12，10, 和 11倍。ACY-1215最低活性作用于(IC50>1μM) HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1,和 Sirtuin2,对HDAC8(IC50=0.1μM)具有轻微的作用活性。ACY-1215作用于T细胞毒性的IC50值为2.5μM。ACY-1215作用于骨髓（BM）环境，克服BMSCs和细胞因子赋予的肿瘤细胞生长和存活。ACY-1215与Bortezomib联用，诱导协同抗MM活性。ACY-1215在非常低的剂量时，诱导强有力的α-tubulin乙酰化，只有在较高剂量时，触发组蛋白H3和H4组蛋白赖氨酸的乙酰化，证实其对HDAC6活性的特定抑制效果。[1] | |||
|---|---|---|---|---|
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | Ac-β-catenin(K49) / p-β-catenin / β-catenin PI3K(p85) / AKT / p-AKT(S473) / PRAS40 / Rag C / mTOR / p-mTOR / ERK / p-ERK Bax / Bim / Bcl2 / Cleaved caspase-3 / Cleaved caspase-9 / Cleaved PARP Survivin / P21 / CDC2 / p53 / p-p53(S392) / Cyclin A2 / Cyclin B1 Ac-α-tubulin / Ac-Histone H4 |
|
25546293 | |
| Immunofluorescence | β-tubulin / β-catenin |
|
25546293 | |
| Growth inhibition assay | Cell viability |
|
31015208 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | ACY-1215与Bortezomib 联用，作用于两个浆细胞瘤模型和弥散性MM模型，抑制肿瘤生长，并延长生存，没有显著的不利影响。比单独使用具有更显著的抗MM 活性。ACY-1215易被肿瘤组织吸收。此外，药物不会在肿瘤组织中累积，处理24小时后，血液细胞和肿瘤组织的乙酰化的α-tubulin平行下降。[1] | |
|---|---|---|
| 动物实验 | Animal Models | MM移植瘤SCID小鼠模型 |
| Dosages | 50 mg/kg | |
| Administration | 腹腔注射 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02632071 | Completed | Metastatic Breast Cancer|Breast Carcinoma |
Columbia University|Acetylon Pharmaceuticals Incorporated|National Cancer Institute (NCI) |
March 1 2016 | Phase 1 |
| NCT01583283 | Completed | Multiple Myeloma |
Celgene |
July 12 2012 | Phase 1 |
| NCT01323751 | Completed | Multiple Myeloma |
Celgene|The Leukemia and Lymphoma Society |
July 2011 | Phase 1|Phase 2 |
化学信息&溶解度
| 分子量 | 433.5 | 分子式 | C24H27N5O3 |
| CAS号 | 1316214-52-4 | SDF | Download Ricolinostat (ACY-1215) SDF |
| Smiles | C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 42 mg/mL ( (96.88 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
常见问题及建议解决方法
问题 1:
What would you suggest to obtain a clear solution?
回答：
S8001 ACY-1215 can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 5 mg/ml clearly while it in 1% DMSO/30% polyethylene glycol/1% Tween 80 at 30 mg/ml is a suspension for oral administration. Please note that the precipitation will go out from the clear solution after stayed for about half an hour, So it is recommended to prepare the solution just before use.
Tags: buy Ricolinostat (ACY-1215) | Ricolinostat (ACY-1215) supplier | purchase Ricolinostat (ACY-1215) | Ricolinostat (ACY-1215) cost | Ricolinostat (ACY-1215) manufacturer | order Ricolinostat (ACY-1215) | Ricolinostat (ACY-1215) distributor
